公开(公告)号：US20230167158A1

公开(公告)日：2023-06-01

申请号：US18096167

申请日：2023-01-12

Applicant: ICHILOV TECH LTD. ,  YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Amer M NAJJAR ,  Anat GLOBERSON LEVIN ,  Tova WAKS ,  Galit HORN

IPC: C07K14/005 ,  C07K16/28 ,  C07K14/705 ,  A61P35/00

CPC classification number: C07K14/005 ,  C07K16/2809 ,  C07K14/70517 ,  A61P35/00 ,  C12N2760/20023 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2760/20222 ,  C12N2760/20242 ,  C12N2760/20271 ,  A61K2039/505

Abstract: The present invention discloses a fusion protein comprising a vesicular stomatitis virus envelope glycoprotein (VSVG) extracellular domain or a fragment or an analog thereof linked to a polypeptide comprising an antigen binding domain specific to cluster of differentiation 3 (CD3). The application also discloses pseudotyped viruses comprising the fusion protein and pseudotyped viruses encoding for a chimeric antigen receptor (CAR) or T-cell receptor pseudotyped in which the receptor is expressed under a CD3 promoter. Pseudotyped viruses combining these properties are encompassed as well. The application further discloses use of these pseudotyped viruses and method of producing these pseudotyped viruses.

公开(公告)号：US20230058044A1

公开(公告)日：2023-02-23

申请号：US17779704

申请日：2020-11-25

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD. ,  ICHILOV TECH LTD. ,  YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Vered PADLER-KARAVANI ,  Yafit ATIYA-NASAGI ,  Ron AMON ,  Anat GLOBERSON LEVIN ,  Tova WAKS ,  Moran RAWET-SLOBODKIN ,  Lihi NINIO MANY ,  Zelig ESHHAR

IPC: A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C07K14/735 ,  C12N5/0783

Abstract: The present invention discloses chimeric antigen receptors that specifically recognize and bind to SLe A carbohydrate antigen with high specificity and selectivity. The invention further provides lymphocytic cells, such as T cells, comprising said CARs, compositions comprising said cells or CARs as well as uses thereof.

公开(公告)号：US20230321235A1

公开(公告)日：2023-10-12

申请号：US18020441

申请日：2021-08-11

Applicant: Yeda Research and Development Co. Ltd. ,  Ichilov Tech Ltd.

Inventor： Yair REISNER ,  Anat GLOBERSON LEVIN ,  Esther BACHAR-LUSTIG ,  Assaf LASK ,  Bar NATHANSOHN-LEVI ,  Tova WAKS ,  Galit HORN ,  Zelig ESHHAR

IPC: A61P35/00 ,  C12N5/0783 ,  A61K39/00

CPC classification number: A61K39/4611 ,  A61K39/4631 ,  A61P35/00 ,  C12N5/0636 ,  A61K2239/22 ,  C12N2510/00

Abstract: A method of generating a population of genetically modified veto cells is disclosed. The method comprising: (a) providing a population of cells comprising T cells, the T cells comprising at least 40% memory CD8+ T cells; (b) culturing the population of cells comprising T cells with an antigen or antigens under conditions which allow enrichment of tolerance-inducing antigen-specific cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being depleted of graft versus host (GVH) reactivity; and (c) transducing the cells with a polynucleotide encoding a heterologous cell surface receptor comprising a T cell receptor signaling module, thereby generating the population of genetically modified veto cells.

公开(公告)号：US20220204928A1

公开(公告)日：2022-06-30

申请号：US17604169

申请日：2020-04-16

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  ICHILOV TECH LTD.

Inventor： Anat AHARON ,  Anat GLOBERSON LEVIN ,  Irit AVIVI ,  Galit HORN ,  Tova WAKS ,  Zelig ESHHAR

IPC: C12N5/0783 ,  C07K16/32 ,  C07K14/705 ,  C07K14/725 ,  A61K45/06 ,  A61K39/395 ,  A61K38/17 ,  A61P35/00 ,  A61K35/17 ,  C07K16/28

Abstract: The present invention provides extracellular vesicles (EVs) derived from T-cells expressing chimeric antigen receptors (CAR) specifically activated with an antigen to which the CAR bind specifically, pharmaceutical compositions comprising these vesicles as well as their use in treating cancer. In particular the present invention exemplifies EVs derived from activated T-cells expressing CAR that bind specifically to HER2 cancer antigen, pharmaceutical composition comprising these EVs and their use in treating a cancer overexpressing HER2, such as ovarian cancer and breast cancer.

公开(公告)号：US20240139247A1

公开(公告)日：2024-05-02

申请号：US18408385

申请日：2024-01-09

Applicant: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER ,  YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Zelig ESHHAR ,  Tova WAKS ,  Anat GLOBERSON LEVIN ,  Moran RAWET SLOBODKIN

IPC: A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/63

CPC classification number: A61K35/17 ,  A61K39/001126 ,  A61K39/001129 ,  A61K39/3955 ,  A61K39/39558 ,  A61K39/4631 ,  A61P35/00 ,  C07K16/28 ,  C07K16/2896 ,  C07K16/3061 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/63 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2319/03

Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 scFv and the second CAR anti-CD138 scFv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.

公开(公告)号：US20240216510A1

公开(公告)日：2024-07-04

申请号：US18556172

申请日：2022-04-13

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD. ,  ICHILOV TECH LTD. ,  YEDA RESEARCH & DEVELOPMENT CO. LTD.

Inventor： Vered PADLER-KARAVANI ,  Ron AMON ,  Lihi NINIOMANY ,  Moran RAWET SLOBODKIN ,  Anat GLOBERSON LEVIN ,  Tova WAKS ,  Zelig ESHHAR

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783

CPC classification number: A61K39/4631 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/464474 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70532 ,  C07K14/70575 ,  C07K14/70578 ,  C07K16/30 ,  C12N5/0636 ,  A61K2039/505 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/30 ,  C12N2510/00

Abstract: The present invention discloses chimeric antigen receptors that specifically recognize and bind to Sialyl Tn carbohydrate antigen with high specificity and selectivity. The invention further provides lymphocytic cells, such as T cells, comprising said CARs, compositions comprising said cells or CARs as well as uses thereof.